Clinical Trials Logo

Clinical Trial Summary

This study is to determine the prevalence and geographical distribution of antimalarial drug resistance-linked genetic mutations in clinical P. falciparum infections in the Greater Mekong Subregion


Clinical Trial Description

This is a prospective observational study of patients with clinical Plasmodium falciparum infection using parasite DNA from point-of-care fingerprick dried blood spot samples as well as a short survey on patient demographics, employment, travel, and mobile phone use to study P. falciparum parasite genotypes, population characteristics, and gene flow patterns.

On inclusion in the study and before standard treatment is administered, dried blood spots (DBS) will be obtained through fingerprick blood sampling from patients, with three blood spots on one piece of filter paper being obtained from each patient. Each blood spot will contain ~20µl of blood, for a total of ~60µl of blood being collected from each patient for the study.

In order to have a greater understanding of the possible sites of malaria transmission and to relate genetic diversity to geographic location, patients or their parents/guardians will also be asked a short set of questions on demographics, their places of residence and work, recent mobile phone use, and their history of travel. The basic questions on phone utilisation will provide information on the use of mobile phones in the study population, including which mobile phone companies are used, and how many SIM cards and handsets each person carries. It will be employed to derive information on population movement from anonymised, aggregated data on mobile phone telephone use, i.e. call detail records (CDR), obtained from mobile phone companies in each country. This will be used for the modelling of population movement, its impact on the distribution of malaria and antimalarial drug resistance, and subsequent prediction of potential routes of spread of malaria and antimalarial drug resistance. As some of this information can be sensitive, during the consent process the patient will be given the option of not providing some or all of this information without needing to provide a reason. For those who do not wish to provide information, this will be documented in the survey form. A duplicate of the sample barcode will be placed on this same form, so the information therein can be matched with the relevant blood spot and its related genetic data, while retaining sample anonymity.

All patients in the study will receive standard care for falciparum malaria including drug therapy according to the national treatment guidelines of their country. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03384498
Study type Observational
Source University of Oxford
Contact Olivo Miotto, MD
Email Olivo@tropmedres.ac
Status Recruiting
Phase N/A
Start date October 2016
Completion date December 2020

See also
  Status Clinical Trial Phase
Completed NCT01935882 - Low Dose Primaquine for Clearance of Gametocytes Phase 2/Phase 3
Completed NCT01728701 - Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis Phase 1
Completed NCT01775592 - Plasmodium Falciparum Artemisinin Resistance Vietnam Phase 4
Completed NCT00914225 - Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya N/A
Completed NCT02895568 - Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers
Completed NCT02259426 - Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission Phase 3
Completed NCT01465048 - Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe N/A
Active, not recruiting NCT00392015 - NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1 Phase 1/Phase 2
Active, not recruiting NCT03138096 - Safety and Protective Efficacy of Pb(PfCS@UIS4) Phase 1/Phase 2
Completed NCT00295581 - PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria Phase 1
Recruiting NCT01322581 - A Longitudinal Systems Biological Analysis of Naturally Acquired Malaria Immunity in Mali
Completed NCT02418962 - Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean Adults Phase 1
Not yet recruiting NCT03452475 - Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children Phase 3
Completed NCT01160562 - Pilot Study to Estimate the Burden and Distribution of Plasmodium Falciparum Malaria in Kalifabougou, Mali in Preparation for a Prospective Cohort Study of Naturally-Acquired Malaria Immunity
Completed NCT03132402 - ELISA Validation of Hypersensitive Rapid Diagnostic Test Results for Detection of P. Falciparum
Recruiting NCT03172221 - Clinical Performance of the HRP2 HS-RDT for Malaria Diagnosis in Pregnant Women N/A
Not yet recruiting NCT03219281 - Prevalence Survey of Antimalarial Drug Resistance Markers at Sites in India N/A
Completed NCT02090036 - Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes Phase 4
Completed NCT00197054 - A Study to Evaluate Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, Two Candidate Malaria Vaccines in Malaria-experienced Adults Living in Western Kenya. Phase 2
Completed NCT01930331 - Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO Phase 4